GleamWall
中文EN

ZYME Zymeworks Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1937653 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY97.8%
TTM net income YoY168.3%
TTM EPS YoY162.4%
Revenue 3-yr CAGR-16.8%
Net income 3-yr CAGR-40.5%

Margins

Gross margin—
Operating margin16.6%
Net margin16.3%
FCF margin-42.4%
EBITDA margin18.0%

Returns

ROE15.0%
ROA5.5%
ROIC (approx.)11.7%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets78.0%
Debt / equity1.31x
Current ratio3.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.59x
Accruals ratio19.7%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$256.46M$4.59M$2.41M$2.52M$27.61M$48.73M$27.11M$31.03M
R&D expense$36.13M$27.43M$34.46M$31.23M$35.58M$34.45M$35.74M$37.06M
SG&A expense$42.74M$19.34M$15.07M$15.43M$14.15M$14.95M$16.98M$16.18M
Operating income$177.60M-$42.18M-$47.12M-$44.15M-$22.11M-$674,000-$25.61M-$22.22M
Pretax income$173.25M-$45.29M-$46.35M-$41.48M-$18.27M$2.13M-$22.14M-$17.79M
Income tax-$452,000-$273,000-$2.19M-$270,000$1.34M-$186,000$496,000$5.71M
Net income$173.70M-$45.02M-$44.16M-$41.21M-$19.60M$2.32M-$22.64M-$23.51M
EBITDA$178.54M-$41.22M-$46.16M-$43.25M-$21.20M$211,000-$24.63M-$21.22M
EPS (basic)2.43-0.62-0.59—-0.260.03-0.30—
EPS (diluted)2.28-0.62-0.59—-0.260.03-0.30—
Weighted avg. shares (diluted)76.25M72.99M74.69M—75.78M77.38M75.23M—
Balance sheet
Cash & equivalents$100.46M$179.41M$244.28M$41.16M$64.83M$98.25M$76.20M$66.10M
Receivables$413.86M$5.93M$4.67M$4.64M$29.35M$2.63M$24.59M$55.81M
Current assets$532.40M$298.39M$385.68M$248.77M$291.71M$296.13M$306.47M$300.45M
PP&E, net$17.91M$13.96M$14.85M$15.50M$15.82M$16.31M$16.68M$17.65M
Goodwill$116.40M$12.02M$12.02M$12.02M$12.02M$12.02M$12.02M$12.02M
Intangibles$823,000$998,000$1.17M$1.35M$1.40M$2.04M$3.36M$4.58M
Total assets$1.18B$396.96M$478.21M$346.53M$397.27M$408.38M$425.52M$463.09M
Current liabilities$161.46M$47.24M$35.65M$42.32M$42.04M$38.50M$65.10M$88.29M
Long-term debt$338.95M———————
Total debt$338.95M———————
Total liabilities$918.16M$316.60M$314.63M$78.03M$77.20M$73.88M$100.56M$124.32M
Shareholders' equity$258.25M$80.37M$163.59M$268.50M$320.06M$334.51M$324.97M$338.77M
Net debt$238.48M———————
Shares outstanding71.18M71.41M73.10M74.64M75.14M74.85M69.58M68.96M
Cash flow statement
Operating cash flow-$24.04M-$31.95M-$45.72M-$10.26M-$31.41M$12.07M-$3.41M-$41.51M
Capital expenditure$73,000$0$216,000$581,000$410,000$514,000$16,000$314,000
Free cash flow-$24.11M-$31.95M-$45.93M-$10.84M-$31.82M$11.56M-$3.42M-$41.82M
Investing cash flow-$389.77M$17.07M$69.96M$5.37M$368,000$8.74M$12.18M-$6.21M
Financing cash flow$334.85M-$50.02M$178.79M-$18.74M-$2.45M$1.32M$1.32M-$8.64M
Depreciation & amortization$941,000$957,000$963,000$898,000$905,000$885,000$981,000$997,000
Stock-based compensation$23.08M$11.33M$6.93M$8.85M$6.91M$5.87M$6.40M$5.02M
Share buybacks$11.99M$51.95M$76.15M$25.48M$16.22M$0$0$9.43M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.